Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.On CNBC's “Mad Money Lightning Round,” Jim Cramer said no to Viking Therapeutics, Inc. VKTX.VKTX is showing downward bias. Get the latest updates here.On Tuesday, Viking Therapeutics released the much ...